Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
about
The concept of treatment-free remission in chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaThe value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution ExperienceSingle cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialUltra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.
P2860
Q26748733-8FE6315B-37DE-4FC2-8328-5E7D11168AEEQ26749324-683375BA-28FF-42CF-B207-70D67E1CDACCQ30491107-F7807231-1936-4FFB-B736-D91FB75842D1Q33439536-0475FE21-D8BA-4FCA-B47B-5BA2B1ED6D53Q33890580-39E073F5-9D61-436D-B1F2-2C39F1155C57Q33899734-56ABB466-8E47-43AA-B3C3-21F1DAD7478DQ37366701-8220547B-3F28-48B6-99EB-99DDE07B16E8Q38376612-7C5BD6D7-BB12-4576-A9DC-C87650D015BDQ38389475-0D6EB315-44C6-472B-97A7-18B9D233F498Q38797683-C7E73082-4AAD-4EEE-8A27-87E43A19A51AQ38845834-DD34D3A0-E31B-4EE2-B7B5-CDA79EFAC823Q38937497-DB416E64-5B55-4B7F-B295-EE6268A0E3B4Q39259447-24B964F8-80FD-41C8-BFC0-259B50AC3D2AQ39446340-5FE6F730-A28E-412A-88C1-91F9B84997C2Q39924810-54EC6A87-409C-4C96-B897-DB6B9DCDC2EFQ40302552-A5909F91-0441-4253-B916-0107765EF9FAQ40807968-7FFE2A31-26CD-4A57-A60F-3403DA52E8C7Q40973173-73CCB6E0-6122-43FB-BCFC-FF947FDA47FAQ46007169-FA4D2C26-A1B0-4823-84AC-99B90BF75979Q47149685-906925A5-BD93-41CF-BFCB-83E38A7F272CQ50421953-2065B22F-8108-4CBE-B224-7E89276DBACAQ53077187-2321F7BC-B7E9-41D7-BF23-22D66350CBB4Q54217429-ED3919CE-A116-489A-91B6-E15ABD218ACEQ55005455-F072B2F7-C175-4B73-AB89-9B9DC6855771
P2860
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Frontline nilotinib in patient ...... m the European ENEST1st study.
@ast
Frontline nilotinib in patient ...... m the European ENEST1st study.
@en
type
label
Frontline nilotinib in patient ...... m the European ENEST1st study.
@ast
Frontline nilotinib in patient ...... m the European ENEST1st study.
@en
prefLabel
Frontline nilotinib in patient ...... m the European ENEST1st study.
@ast
Frontline nilotinib in patient ...... m the European ENEST1st study.
@en
P2093
P2860
P50
P356
P1433
P1476
Frontline nilotinib in patient ...... om the European ENEST1st study
@en
P2093
A Hellmann
A Pellegrino
G Ossenkoppele
J L Steegmann
L Griskevicius
P2860
P2888
P356
10.1038/LEU.2015.270
P577
2015-10-06T00:00:00Z